Cargando…

Characterization of a novel MEF2D-BCL9 fusion-positive acute lymphoblastic leukemia cell line

Detalles Bibliográficos
Autores principales:	van Outersterp, Inge, Hormann, Femke M., Hoogkamer, Alex Q., Boeree, Aurélie, van den Broek, Stijn A., den Boer, Monique L., Boer, Judith M.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Fondazione Ferrata Storti 2023
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10542830/ https://www.ncbi.nlm.nih.gov/pubmed/37051743 http://dx.doi.org/10.3324/haematol.2022.281712

Ejemplares similares

Integrating copy number data of 64 iAMP21 BCP-ALL patients narrows the common region of amplification to 1.57 Mb
por: Hormann, Femke M., et al.
Publicado: (2023)

Copy number alterations in B-cell development genes, drug resistance, and clinical outcome in pediatric B-cell precursor acute lymphoblastic leukemia
por: Steeghs, Elisabeth M. P., et al.
Publicado: (2019)

JAK2 aberrations in childhood B-cell precursor acute lymphoblastic leukemia
por: Steeghs, Elisabeth M.P., et al.
Publicado: (2017)

Fibroblast growth factor receptor signaling in pediatric B-cell precursor acute lymphoblastic leukemia
por: Jerchel, Isabel S., et al.
Publicado: (2019)

Tyrosine kinase fusion genes in pediatric BCR-ABL1-like acute lymphoblastic leukemia
por: Boer, Judith M., et al.
Publicado: (2016)

ABL-class Genomic Breakpoint Q-PCR: A Patient-specific Approach for MRD Monitoring in Acute Lymphoblastic Leukemia
por: van Outersterp, Inge, et al.
Publicado: (2023)

High STAP1 expression in DUX4-rearranged cases is not suitable as therapeutic target in pediatric B-cell precursor acute lymphoblastic leukemia
por: Steeghs, Elisabeth M. P., et al.
Publicado: (2018)

Ibrutinib is not an effective drug in primografts of TCF3-PBX1
por: van de Ven, Cesca, et al.
Publicado: (2020)

RAS pathway mutations as a predictive biomarker for treatment adaptation in pediatric B-cell precursor acute lymphoblastic leukemia
por: Jerchel, I S, et al.
Publicado: (2018)

PB1706: ABL-CLASS GENOMIC BREAKPOINT Q-PCR FOR RELIABLE MEASURABLE RESIDUAL DISEASE MONITORING IN ALL PATIENTS
por: van Outersterp, Inge, et al.
Publicado: (2023)

Minimal residual disease (MRD) detection in acute lymphoblastic leukaemia based on fusion genes and genomic deletions: towards MRD for all
por: Kuiper, Roland P., et al.
Publicado: (2021)

Genomic analyses identify recurrent MEF2D fusions in acute lymphoblastic leukaemia
por: Gu, Zhaohui, et al.
Publicado: (2016)

Clinical and molecular characteristics of MEF2D fusion-positive B-cell precursor acute lymphoblastic leukemia in childhood, including a novel translocation resulting in MEF2D-HNRNPH1 gene fusion
por: Ohki, Kentaro, et al.
Publicado: (2019)

BCL2 Inhibitor (ABT-737): A Restorer of Prednisolone Sensitivity in Early T-Cell Precursor-Acute Lymphoblastic Leukemia with High MEF2C Expression?
por: Kawashima-Goto, Sachiko, et al.
Publicado: (2015)

Knockdown of MEF2D inhibits the development and progression of B-cell acute lymphoblastic leukemia
por: Chang, Ning, et al.
Publicado: (2023)

Autophagy inhibition as a potential future targeted therapy for ETV6-RUNX1-driven B-cell precursor acute lymphoblastic leukemia
por: Polak, Roel, et al.
Publicado: (2019)

The Prognostic Effect of IKZF1 Deletions in ETV6::RUNX1 and High Hyperdiploid Childhood Acute Lymphoblastic Leukemia
por: Østergaard, Anna, et al.
Publicado: (2023)

Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients
por: Scheijen, Blanca, et al.
Publicado: (2017)

A typical bedside-to-bench investigation of leukemogenic driver MEF2D fusion reveals new targeted therapy in B-cell acute lymphoblastic leukemia
por: Zhang, Hao, et al.
Publicado: (2022)

Identification of Genes Transcriptionally Responsive to the Loss of MLL Fusions in MLL-Rearranged Acute Lymphoblastic Leukemia
por: van der Linden, Marieke H., et al.
Publicado: (2015)

BCL6 modulation of acute lymphoblastic leukemia response to chemotherapy
por: Slone, William L., et al.
Publicado: (2016)

Conserved IKAROS-regulated genes associated with B-progenitor acute lymphoblastic leukemia outcome
por: Witkowski, Matthew T., et al.
Publicado: (2017)

Favorable outcome of NUTM1-rearranged infant and pediatric B cell precursor acute lymphoblastic leukemia in a collaborative international study
por: Boer, Judith M., et al.
Publicado: (2021)

P316: PRIORITIZING PRECISION MEDICINES IN PEDIATRIC BLOOD CANCER: EXPERIENCE OF THE DUTCH INDIVIDUALIZED THERAPY (ITHER) STUDY’S MOLECULAR TUMOR BOARD
por: Boer, Judith M., et al.
Publicado: (2023)

Rationale for targeting BCL6 in MLL-rearranged acute lymphoblastic leukemia
por: Hurtz, Christian, et al.
Publicado: (2019)

RBP2 Promotes Adult Acute Lymphoblastic Leukemia by Upregulating BCL2
por: Wang, Xiaoming, et al.
Publicado: (2016)

Asparaginase-associated toxicity in children with acute lymphoblastic leukemia
por: Hijiya, Nobuko, et al.
Publicado: (2016)

Acute B lymphoblastic leukaemia-propagating cells are present at high frequency in diverse lymphoblast populations
por: Rehe, Klaus, et al.
Publicado: (2013)

P342: RAS PATHWAY ACTIVATION REMODELS THE BONE MARROW MICROENVIRONMENT IN ACUTE LYMPHOBLASTIC LEUKAEMIA
por: Ferrao Blanco, Mauricio, et al.
Publicado: (2023)

Bcl-xl as the most promising Bcl-2 family member in targeted treatment of chondrosarcoma
por: de Jong, Yvonne, et al.
Publicado: (2018)

Functional inhibition of MEF2 by C/EBP is a possible mechanism of leukemia development by CEBP‐IGH fusion gene
por: Odaira, Koya, et al.
Publicado: (2022)

Therapeutic Targeting of MERTK and BCL-2 in T-Cell and Early T-Precursor Acute Lymphoblastic Leukemia
por: Summers, Ryan J., et al.
Publicado: (2022)

Population pharmacokinetics of intravenous Erwinia asparaginase in pediatric acute lymphoblastic leukemia patients
por: Sassen, Sebastiaan D.T., et al.
Publicado: (2017)

ZNF384-Related Fusion Genes in Acute Lymphoblastic Leukemia
por: Zhu, Liwen, et al.
Publicado: (2023)

BCL6 inhibition ameliorates resistance to ruxolitinib in CRLF2-rearranged acute lymphoblastic leukemia
por: Tsuzuki, Shinobu, et al.
Publicado: (2022)

Acute Activation of Metabolic Syndrome Components in Pediatric Acute Lymphoblastic Leukemia Patients Treated with Dexamethasone
por: Warris, Lidewij T., et al.
Publicado: (2016)

Interference with pre-B-cell receptor signaling offers a therapeutic option for TCF3-rearranged childhood acute lymphoblastic leukemia
por: van der Veer, A, et al.
Publicado: (2014)

Clonal heterogeneity and rates of specific chromosome gains are risk predictors in childhood high‐hyperdiploid B‐cell acute lymphoblastic leukemia
por: Ramos‐Muntada, Mireia, et al.
Publicado: (2022)

Sleep–wake rhythm disruption is associated with cancer-related fatigue in pediatric acute lymphoblastic leukemia
por: Steur, Lindsay M H, et al.
Publicado: (2019)

Copy Number Alterations in CDKN2A/2B and MTAP Genes Are Associated With Low MEF2C Expression in T-cell Acute Lymphoblastic Leukemia
por: Kumari, Sarita, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_7jjoirnugae41lplmdd8bqki58